{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:09:28Z","timestamp":1784023768977,"version":"3.55.0"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO Oncol Adv"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>S1826 was an international phase III randomized trial that demonstrated improved progression-free survival (PFS) of nivolumab plus doxorubicin, vinblastine, and dacarbazine (N + AVD) over brentuximab vedotin plus AVD (BV + AVD) in newly diagnosed advanced-stage classic Hodgkin lymphoma (cHL). Here we report results of enrolled participants with HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      People with HIV (PWH) with a CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cell above \u2265200 cells\/\u00b5L and on effective antiretroviral therapy with an undetectable HIV viral load within 6 months before enrollment were eligible. Participants were randomly assigned in a 1:1 ratio to receive six 28-day cycles of either N + AVD or BV + AVD intravenously. The primary end point was PFS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Sixteen eligible PWH were enrolled, 11 received N + AVD and five received BV + AVD. The median follow-up duration was 32.7 months in the N + AVD arm and 26.7 months in the BV + AVD arm. The 2-year PFS rate was 77.9% in the N + AVD arm and 75.0% in the BV + AVD arm. The 2-year OS was 85.7% in the N + AVD arm and 75.0% in the BV + AVD arm. Grade \u22653 adverse events were observed in 45% of participants in the N + AVD arm and 50% in the BV + AVD arm with more frequent febrile neutropenia and severe infections were observed in the BV + AVD arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>N + AVD is safe and effective in newly diagnosed HIV-associated advanced-stage cHL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/oa-25-00143","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:59:18Z","timestamp":1772139558000},"source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma"],"prefix":"10.1200","volume":"3","clinical-trial-number":[{"clinical-trial-number":"nct03907488","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5177","authenticated-orcid":true,"given":"Gaurav","family":"Goyal","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-7292","authenticated-orcid":true,"given":"Kathryn","family":"Lurain","sequence":"additional","affiliation":[{"name":"Ohio State University James Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4174-9071","authenticated-orcid":true,"given":"Gabby","family":"Lopez","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-7727","authenticated-orcid":true,"given":"Sarah C.","family":"Rutherford","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-2002","authenticated-orcid":true,"given":"Sharon","family":"Castellino","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University Hospital\/Winship Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-3916","authenticated-orcid":true,"given":"Kelly","family":"Davison","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-1824","authenticated-orcid":true,"given":"Andrew","family":"Evens","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-3937","authenticated-orcid":true,"given":"Kara","family":"Kelly","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, University at Buffalo, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-2513","authenticated-orcid":true,"given":"Joo Y.","family":"Song","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1644-2378","authenticated-orcid":true,"given":"Thomas","family":"Odeny","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, Washington University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2744-7294","authenticated-orcid":true,"given":"Lee","family":"Ratner","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, Washington University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":true,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr076"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024109"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-551598"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206125"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00157-6"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00005-X"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007400"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00315"},{"key":"e_1_3_9_12_2","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch RC","year":"2023","unstructured":"Lynch RC, Ujjani CS, Poh C, et al: Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood 141:2576-2586, 2023","journal-title":"Blood"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02355"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009178"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015423"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01056"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7975"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_3_9_22_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.clml.2024.03.011","article-title":"Real-world multicenter study of PD-1 blockade in HIV-associated classical hodgkin lymphoma across the United States","volume":"24","author":"Lurain K","year":"2024","unstructured":"Lurain K, Zarif TE, Ramaswami R, et al: Real-world multicenter study of PD-1 blockade in HIV-associated classical hodgkin lymphoma across the United States. Clin Lymphoma Myeloma Leuk 24:523-530, 2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_9_25_2","unstructured":"U.S. Department of Health and Human Services: National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt158"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1201573"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1119"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01315-1"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02459"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00640"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2244"}],"container-title":["JCO Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OA-25-00143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:20:55Z","timestamp":1775143255000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OA-25-00143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1200\/OA-25-00143"],"URL":"https:\/\/doi.org\/10.1200\/oa-25-00143","relation":{},"ISSN":["2994-9750"],"issn-type":[{"value":"2994-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e2500143"}}